Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Generalized Myasthenia GravisAnti-AChR Antibody Positive
Interventions
DRUG

Ravulizumab

Participants will receive Ravulizumab.

Trial Locations (20)

Unknown

RECRUITING

Clinical Trial Site, Bergamo

NOT_YET_RECRUITING

Clinical Trial Site, Bologna

NOT_YET_RECRUITING

Clinical Trial Site, Brescia

RECRUITING

Clinical Trial Site, Florence

NOT_YET_RECRUITING

Clinical Trial Site, Imperia

RECRUITING

Clinical Trial Site, Lecco

NOT_YET_RECRUITING

Clinical Trial Site, Messina

NOT_YET_RECRUITING

Clinical Trial Site, Milan

NOT_YET_RECRUITING

Clinical Trial Site, Napoli

NOT_YET_RECRUITING

Clinical Trial Site, Novara

NOT_YET_RECRUITING

Clinical Trial Site, Orbassano

NOT_YET_RECRUITING

Clinical Trial Site, Padua

NOT_YET_RECRUITING

Clinical Trial Site, Palermo

NOT_YET_RECRUITING

Clinical Trial Site, Parma

NOT_YET_RECRUITING

Clinical Trial Site, Pavia

NOT_YET_RECRUITING

Clinical Trial Site, Pisa

NOT_YET_RECRUITING

Clinical Trial Site, Roma

NOT_YET_RECRUITING

Clinical Trial Site, Salerno

NOT_YET_RECRUITING

Clinical Trial Site, Sassari

NOT_YET_RECRUITING

Clinical Trial Site, Torino

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY